



ASX ANNOUNCEMENT

1 October 2026

FY2026 Annual Report, creditor update and Board changes

Sydney, Australia, 1 October 2026: Chimeric Therapeutics Limited (ASX: CHM) (**Chimeric** or the **Company**), a leading Australian cell therapy company, provides this update in relation its FY2026 Financial Statements, negotiations with creditors and Board changes.

Key Points

- Chimeric's securities are suspended from trading under Listing Rule 17.5 because the Company's FY2026 Financial Statements have not been filed by the due date of 30 September 2026
- Chimeric has a deficiency of net assets and is negotiating with its creditors, including its convertible note holder, to settle its liabilities
- Several parties have expressed interest in recapitalising the Company, conditional on a satisfactory creditor outcome. There is no formal or binding proposal at this stage
- Board changes effective immediately: Phillip Hains appointed Interim Chairman, CEO Dr Rebecca McQualter appointed as Managing Director, Brad Glover and Lesley Russell retire from Board

Phillip Hains, Interim Chair of Chimeric commented:

"The suspension follows from the full year financial statements not being lodged by 30 September 2026. Settling our liabilities with creditors is the first step necessary to complete the financial statements and is a condition of any recapitalisation. We appreciate the engagement of our creditors to date and will continue to work with them to reach an outcome as soon as practicable. We continue to carefully manage our current financial resources and have taken further steps to cut costs, including downsizing our Board. On behalf of the Board, I thank Brad and Lesley for their contribution to Chimeric."

FY2026 Annual Report

Release of the FY2026 Financial Statements has been delayed pending negotiation of unconditional agreements with creditors and a recapitalisation.

The Company expects that its securities will remain suspended from the ASX until the audited FY2026 Financial Statements are lodged and ASX is satisfied that the Company has met its requirements for reinstatement.



Financial position

As disclosed on 31 August 2026, the Company's FY2026 Financial Statements are expected to include a material uncertainty in relation to going concern. The Preliminary Final Report lodged on 31 August 2026 reported a deficiency of net assets of approximately \$7.7 million. The Company has reduced its activities to care and maintenance while the matters below are progressed.

Creditor negotiations

The Company continues to negotiate with its creditors, including the holder of its convertible notes, to settle its liabilities on an unconditional basis. The intention is to negotiate the Company's valid and agreed liabilities to a level able to be satisfied by the Company's current financial resources, with binding deeds of settlement. No agreement has yet been reached, and there is no certainty as to the outcome or timing of these negotiations.

Recapitalisation

Several parties have expressed interest in providing funding to recapitalise the Company. These include a proposal to support a deeply discounted rights issue such that existing shareholders would have the ability to participate. Each expression of interest is conditional, including on a satisfactory outcome with creditors. No binding proposal has been received, and there is no certainty that a recapitalisation will proceed or as to its terms.

Board changes

The Company has significantly reduced its U.S. operations, including in relation to the close out of the Phase I clinical study and a reduction in U.S.-based employees. The CORE NK investigator lead study remains ongoing but requires no funding or support from the Company.

Accordingly, with very limited U.S. operations, the Board has been downsized with immediate effect. Brad Glover and Lesley Russell have retired as directors, Dr Rebecca McQualter, Chief Executive Officer, has been appointed to the Board as Managing Director (with no other change to terms of employment or remuneration), and Phillip Hains has been appointed Interim Chair. The Board comprises Phillip Hains, Miles Prince and Dr Rebecca McQualter.

Continuous disclosure

The Company's continuous disclosure obligations continue to apply while its securities are suspended. The Company will inform the market of material developments as they occur.

Authorised on behalf of the Chimeric Therapeutics by the Board of Directors.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, an Australia clinical stage cell therapy company, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's team of cell therapy pioneers is focused on the discovery, development, and commercialisation of innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies.

For more information visit www.chimerictherapeutics.com or follow us on LinkedIn at www.linkedin.com/company/chimeric-therapeutics.



For more information:

Corporate Enquiries

Dr Rebecca McQualter

Chief Executive Officer and Managing Director

Chimeric Therapeutics

E: investors@chimerictherapeutics.com